BEGIN:VCALENDAR VERSION:2.0 PRODID:-//hacksw/handcal//NONSGML v1.0//EN BEGIN:VEVENT UID:deb2ab5a18bae7931fca3150cb52b1cb DTSTAMP:20260604T162030Z DTSTART:20240222T150000 DTEND:20240222T150000 SUMMARY:GVIRF Webinar: New TB Vaccines for Adults and Adolescents, Progress, Prospects, and Perspectives DESCRIPTION:It’s an exciting time for new TB vaccine development! Several vaccine candidates are in late stage product development, with Phase III trial data available as early as 2024 and potential licensure and use in some countries in the near future. However, none of the candidates are expected to be a ‘silver bullet’ and there are differences in terms of trial design, primary endpoint, target population, and product attributes. Without a known correlate of protection, the effect of HIV status, infection status, age and geography on vaccine efficacy must be determined for each vaccine. We also need to ensure that the early pipeline remains robust in terms of new antigenic targets and platforms, and that new tools are developed to effectively evaluate their potential efficacy.\nThis webinar will bring together experts to discuss the status of TB vaccine development across the value chain, from articulation of the public health and economic need for new TB vaccines, through the status and strategies for product development, to the considerations for approval, policy recommendation and use.\nRegister here: https://who.zoom.us/webinar/register/WN_B1qi05_KT9Om_EaGRhqGBg#/registration X-ALT-DESC;FMTTYPE=text/html:\n\n\n\n\n\n\n\n\n

It’s an exciting time for new TB vaccine development! Several vaccine candidates are in late stage product development, with Phase III trial data available as early as 2024 and potential licensure and use in some countries in the near future. However, none of the candidates are expected to be a ‘silver bullet’ and there are differences in terms of trial design, primary endpoint, target population, and product attributes. Without a known correlate of protection, the effect of HIV status, infection status, age and geography on vaccine efficacy must be determined for each vaccine. We also need to ensure that the early pipeline remains robust in terms of new antigenic targets and platforms, and that new tools are developed to effectively evaluate their potential efficacy.

This webinar will bring together experts to discuss the status of TB vaccine development across the value chain, from articulation of the public health and economic need for new TB vaccines, through the status and strategies for product development, to the considerations for approval, policy recommendation and use.

\n\n\n LOCATION: END:VEVENT END:VCALENDAR